Literature DB >> 11241900

Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.

R Braunschweig1, P Yan, I Guilleret, F Delacretaz, F T Bosman, A Mihaescu, J Benhattar.   

Abstract

Telomerase is inactive in most somatic cells, but has been found to be reactivated in a majority of cancers. Our principal goal was to test whether the presence of telomerase activity concurred with positive cytology, and was thus of potential use in detecting cancer cells in effusions. The telomeric repeat amplification protocol (TRAP) assay and cytological examination were performed in a blinded fashion on 91 unselected effusions, for which laboratory processing was done according to standard procedures. In our series, 30% (27/91) of samples were found to be malignant by cytology. Of these, 19 (70%) were also positive in the TRAP assay. Of the 8 telomerase-negative cytology-positive samples, RNA integrity was generally poor, indicating suboptimal sample conservation for molecular analysis. Negative cytology in the presence of telomerase activity was observed in 17 effusions. Of these, 11 were from patients with advanced cancer, and thus a diagnosis of malignant effusion should be suspected. The TRAP assay for telomerase activity holds promise in the analysis of effusions, but its routine use as an adjunct to cytology awaits further confirmation of its positive predictive value. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241900     DOI: 10.1002/1097-0339(200103)24:3<174::aid-dc1036>3.0.co;2-8

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  8 in total

1.  Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.

Authors:  Fan Zhang; Junjun Wang; Xiaoyong Zheng; Lijuan Hu; Jie Chen; Feng Jiang; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2018-05-23       Impact factor: 2.352

2.  Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion.

Authors:  Fan Zhang; Lijuan Hu; Junjun Wang; Jian Chen; Jie Chen; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2016-12-15       Impact factor: 2.352

3.  Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies.

Authors:  Chung-Pin Li; Tze-Sing Huang; Yee Chao; Full-Young Chang; Jacquline Whang-Peng; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

4.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

5.  Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.

Authors:  Junjun Wang; Jiali Fu; Qiang Shen; Fan Zhang; Yumin Wang; Ling Ling Wu
Journal:  J Clin Lab Anal       Date:  2019-07-03       Impact factor: 2.352

6.  Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion.

Authors:  Fan Zhang; Junjun Wang; Jiali Fu; Lijuan Hu; Xiaoyong Zheng; Yumin Wang; Bicheng Chen
Journal:  J Clin Lab Anal       Date:  2019-11-10       Impact factor: 2.352

7.  Telomerase activity assay for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Zhen-Ni Chen; Ting Yang; Lei Chen; Tao Wang; Fu-Qiang Wen; Qun Yi
Journal:  Exp Ther Med       Date:  2012-06-26       Impact factor: 2.447

8.  Diagnostic yield of cytologic analysis of pericardial effusion in dogs.

Authors:  L A Cagle; S E Epstein; S D Owens; M S Mellema; K Hopper; A G Burton
Journal:  J Vet Intern Med       Date:  2013-11-16       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.